B cells continue to work against SARS-CoV-2 months after infection, but do not recognize mutant

February 23, 2021

A new analysis of B cells and more than 1,000 different monoclonal antibodies from 8 patients with COVID-19 shows that, contrary to previous hypotheses, protective B cell responses to the SARS-CoV-2 spike protein remain stable and continue to evolve over a 5-month period, many months after the initial period of active viral replication. However, a large proportion of the neutralizing antibodies generated from these long-lasting B cells did not efficiently recognize various emerging SARS-CoV-2 variants from Brazil and South Africa. These results - from an academia-industry collaboration - will help inform the design of future COVID-19 vaccines that work to constrain viral evolution and stimulate better neutralizing antibody and B cell responses against emerging SARS-CoV-2 variants. Mrunal Sakharkar and colleagues profiled spike protein-specific B cell and antibody responses in 8 patients with mild and severe COVID-19 over five months. Consistent with previous findings, they observed a significant decline in neutralizing antibody levels in the blood over time; however, levels of spike protein-specific memory B cells remained stable or even increased during the same time frame. As well, over the course of 120 days, monoclonal antibodies isolated from these B cells underwent increased somatic hypermutation, binding affinity, and neutralization potency - all signs of persistent B cell activity. The researchers also observed cross-neutralizing B cell populations, but these comprised just a small fraction of the B cell repertoire and were not prominent in the neutralizing response to SARS-CoV-2. Rather, a large proportion of the neutralizing antibody response only targeted conserved epitopes shared between SARS-CoV-2 and SARS-CoV and did not efficiently recognize emerging SARS-CoV-2 variants from Brazil and South Africa that harbor mutations at amino acid positions 417 and 484 of the spike protein. Thus, the authors suggest careful monitoring of circulating SARS-CoV-2 variants for variability in these protein sites to determine how these mutations impact vaccine-induced immunity.

American Association for the Advancement of Science

Related Monoclonal Antibodies Articles from Brightsurf:

Rapid method finds potent COVID-19 monoclonal antibody among a trillion possibilities
University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19.

NEJM: clinical trial indicates monoclonal antibody lowered hospitalizations and emergency visits
COVID-19 (coronavirus) patients who were administered a novel antibody had fewer symptoms and were less likely to require hospitalization or emergency medical care than those who did not receive the antibody, according to a new study published in the The New England Journal of Medicine.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

A simple screening process may enhance monoclonal antibody-based drug development
By screening potential monoclonal antibody (mAb)-based drugs solely based on a measure of their colloidal stability, scientists may be able to weed out mAbs that do not respond efficiently in solution early in the

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

X-ray experiments zero in on COVID-19 antibodies
An antibody derived from a SARS survivor in 2003 appears to effectively neutralize the coronavirus that causes COVID-19, opening the door for speedy development of a targeted treatment.

Towards antibodies against COVID-19
The lab of Xavier Saelens (VIB-UGent Center for Medical Biotechnology) announces the isolation and characterization of a unique antibody that can bind to the virus that causes COVID-19 (SARS-CoV-2).

Antibodies from llamas could help in fight against COVID-19
Initial tests of a new candidate antibody treatment for COVID-19 indicate that it blocks viruses that display the SARS-CoV-2 spike protein from infecting cells in culture.

Antibodies could provide new treatment for OCD
Mental health conditions such as obsessive compulsive disorder could be treated in a new way using drugs that target the immune system, research suggests.

Read More: Monoclonal Antibodies News and Monoclonal Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.